Core Viewpoint - The stock price of Beijing Baipusi Biotechnology Co., Ltd. has experienced significant fluctuations, with a year-to-date increase of 96.95% but a recent decline of 5.32% over the past five trading days [2]. Company Overview - Beijing Baipusi Biotechnology Co., Ltd. was established on July 22, 2010, and went public on October 18, 2021. The company is located in the Beijing Economic and Technological Development Zone [2]. - The company's main business involves providing key biological reagent products and technical services, with revenue composition as follows: recombinant proteins 82.27%, antibodies and other reagents 12.88%, technical services 3.04%, and others 1.80% [2]. Financial Performance - For the period from January to September 2025, the company achieved operating revenue of 613 million yuan, representing a year-on-year growth of 32.26%. The net profit attributable to the parent company was 132 million yuan, reflecting a year-on-year increase of 58.61% [2]. - Since its A-share listing, the company has distributed a total of 432 million yuan in dividends, with 312 million yuan distributed over the past three years [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders for Baipusi was 10,600, a decrease of 9.75% from the previous period. The average circulating shares per person increased by 54.93% to 11,947 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the second-largest shareholder with 13.56 million shares, an increase of 7.57 million shares from the previous period. Additionally, China Europe Medical Health Mixed A (003095) is the fourth-largest shareholder with 5.99 million shares, up by 2.78 million shares [3].
百普赛斯跌2.03%，成交额1092.49万元，主力资金净流出186.89万元